Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

G-motif oligonucleotides and uses thereof

Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination

The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

Delta-like ligand 1 for diagnosing severe infections

The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.

DELTA-LIKE LIGAND 1 FOR DIAGNOSING SEVERE INFECTIONS

The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis. 1. Use of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein as a biomarker for the in vitro diagnosis of a severe infection.2. The use according to claim 1 , wherein the delta-like ligand 1 protein is encoded by the nucleotide sequence SEQ ID NO: 1.3. The use according to claim 1 , wherein the delta-like ligand 1 protein is a protein having at least 90% identity with the amino acid sequence of SEQ ID NOs: 2 and/or 3.4. The use according to claim 1 , wherein the delta-like ligand 1 protein is a cleavage product of the delta-like ligand 1 protein claim 1 , in particular wherein the cleavage product is a protein having an amino acid sequence of SEQ ID NO: 4 claim 1 , SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 and/or SEQ ID NO: 7.5. The use according to claim 1 , wherein an elevated expression level of delta-like ligand 1 protein or the nucleotide sequence encoding delta-like ligand 1 protein is indicative for the diagnosis of an infection.6. The use according to claim 1 , wherein the severe infection is sepsis.7. The use according to claim 1 , wherein the expression level is determined in a biological sample.8. The use according to claim 7 , wherein the biological sample is selected from the group consisting of whole blood claim 7 , buffy coat claim 7 , plasma claim 7 , serum claim 7 , peripheral blood mononucleated cells (PBMCS) claim 7 , neutrophils claim 7 , monocytes claim 7 , T cells claim 7 , urine claim 7 , spinal fluid claim 7 , ...

Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination

The invention discloses a pharmaceutical composition comprising at least one fragment of a polynucleotide and at least one antigen, especially for the preparation of a vaccine.

G-motif oligonucleotides and uses thereof

The present invention relates to a composition comprising an oligonucleotide comprising (a) the sequence N1-N2-G-N3-G, wherein N1 represents any nucleoti de if N2 and N3 are G; N2 represents any nucleotide if N1 and N3 are G; and N3 represents any nucleotide if N1 and N2 are G, or (b) the sequence of (a), wherein at least one nucleotide is replaced by a corresponding nucleotide analog or derivative. The present invention further relates to the use of th e composition, and/or the oligonucleotide of the present invention for the production of a pharmaceutical composition for preventing or treating septic shock, inflammation, autoimmune diseases, TH1-mediated diseases, bacterial infections, parasitic infections, viral infections, spontaneous abortions, and/or tumors.

G-motif oligonucleotides and uses thereof

The present invention relates to a composition comprising an oligonucleotide comprising (a) the sequence N1-N2-G-N3-G, wherein N1 represents any nucleotide if N2 and N3 are G; N2 represents any nucleotide if N1 and N3 are G; and N3 represents any nucleotide if N1 and N2 are G, or (b) the sequence of (a), wherein at least one nucleotide is replaced by a corresponding nucleotide analog or derivative. The present invention further relates to the use of the composition, and/or the oligonucleotide of the present invention for the production of a pharmaceutical composition for preventing or treating septic shock, inflammation, autoimmune diseases, TH1-mediated diseases, bacterial infections, parasitic infections, viral infections, spontaneous abortions, and/or tumors.

Delta-like ligand 1 for diagnosing severe infections

The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta- like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.

G-Motif Oligonucleotides and Uses Thereof

Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

Multiplex pcr for detection of carbapenemase genes

The present invention relates to a method for determining in a sample the presence or absence of carbapenemase producing bacteria, comprising determining the presence or absence of one or more carbapenemase genes selected from the group consisting of an NDM carbapenemase gene, a KPC carbapenemase gene, a VIM carbapenemase gene, an IMP carbapenemase gene, an OXA-23-like carbapenemase gene, an OXA-48-like carbapenemase gene, an OXA-58-like carbapenemase gene and an OXA-40/24-like carbapenemase gene. In addition, the invention relates to an oligonucleotide set and a kit suitable for use in the claimed method. The invention further relates to a method of diagnosis of an infection with carbapenemase producing bacteria, a method for selecting a patient for treatment with a beta lactam antibacterial drug and a beta lactam antibacterial drug, preferably a carbapenem, for use in a method of treatment of a bacterial infection in a patient that is not infected with carbapenemase producing bacteria.